Last reviewed · How we verify
Dexametasone. Medium
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders, Cerebral edema, Acute respiratory distress syndrome (ARDS).
At a glance
| Generic name | Dexametasone. Medium |
|---|---|
| Sponsor | The Children's Hospital of Zhejiang University School of Medicine |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Inflammation, Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. It is commonly used to manage inflammation, autoimmune conditions, and as an adjunctive therapy in various acute and chronic diseases.
Approved indications
- Inflammatory and autoimmune disorders
- Cerebral edema
- Acute respiratory distress syndrome (ARDS)
- Severe COVID-19
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (agitation, depression)
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: